Skip to main content
. 2018 Apr 23;15(6):5371–5376. doi: 10.3892/etm.2018.6086

Figure 2.

Figure 2.

SphK1 is overactivated in the oxaliplatin-resistant HCC cell lines. qRT-PCR analysis of relative (A) SphK1 and (B) SphK2 mRNA expression levels in four HCC cell lines and normal liver cell line (HL-7702). (C) Western blot analysis of relative SphK1 and SphK2 protein expression levels in four HCC cell lines and normal liver cell line (HL-7702). (D) SphK1 activity was measured by using SphK1 Activity Assay kit. (E) Percentage of survival of cells treated with increasing doses of oxaliplatin (0–60 µg/ml) after 48 h, as measured by the MTT assay. *P<0.05; **P<0.01. SphK, Sphingosine kinase; HCC, hepatocellular carcinoma.